Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

Conclusions: Ruxolitinib led to rapid and durable responses and was well tolerated in adult patients with secondary HLH.DisclosuresDevata: Affimed: Research Funding. Phillips: Abbvie: Research Funding; Pharmacyclics: Consultancy, Research Funding; Genentech: Consultancy; Bayer: Consultancy; Seattle Genetics: Consultancy; Gilead: Consultancy. Sood: Bayer: Research Funding. Wilcox: Incyte, Corp: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Alsawah, F., Merrill, S. A., Bockenstedt, P. L., Campagnaro, E. L., Devata, S., Gitlin, S. D., Kaminski, M. S., Cusick, A. M., Phillips, T. J., Sood, S. L., Talpaz, M., Quiery, A. T., Boonstra, P. S., Ahmed, A. Z., Wilcox, R. A. Tags: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I Source Type: research